Cosmetic cross-reference Noindex: medium evidence

Calcium Alginate

CAS 9005-35-0

Calcium Alginate (CAS 9005-35-0) is a pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE DrugCentral 055904D152D6

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Calcium Alginate
CAS Number
9005-35-0
UNII
8P20S56HZI
ChEMBL ID
CHEMBL3707407
DrugCentral Struct ID
4431
Source Match
DrugCentral (CAS), FDA GSRS (UNII)
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE NLM RxNorm 2 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
CALCIUM ALGINATE 47610 SU MTHSPL
calcium alginate 47610 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Calcium Alginate used for in pharmaceutical contexts?

Calcium Alginate (CAS 9005-35-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Calcium Alginate?

No adverse-event association or SIDER side-effect rows are rendered for Calcium Alginate in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Calcium Alginate also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Calcium Alginate with EU status "permitted".

What clinical phase is Calcium Alginate in?

No phase 1-4 clinical development badge is rendered for Calcium Alginate because the matched compound identifier rows do not contain a max-phase value.